Media coverage
8
Media coverage
Title MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 Media name/outlet Valuespectrum.com Country/Territory United States Date 12/12/22 URL www.valuespectrum.com/corporate_news/868143-morphosys-presents-new-longer-term-phase-2-results-on-pelabresib-in-myelofibrosis-including-potential-disease-modifying-activity-at-ash-2022 Persons John Mascarenhas Title MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 Media name/outlet PharmiWeb Country/Territory United Kingdom Date 11/12/22 URL https://www.pharmiweb.com/press-release/2022-12-11/morphosys-presents-new-longer-term-phase-2-results-on-pelabresib-in-myelofibrosis-including-potenti Persons John Mascarenhas Title MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 Media name/outlet Yahoo! Finance UK and Ireland Country/Territory United Kingdom Date 11/12/22 URL https://uk.finance.yahoo.com/news/morphosys-presents-longer-term-phase-223104864.html Persons John Mascarenhas Title MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 Media name/outlet MarketScreener.com Country/Territory United States Date 11/12/22 URL https://www.marketscreener.com/quote/stock/MORPHOSYS-AG-436425/news/MorphoSys-Presents-New-Longer-term-Phase-2-Results-on-Pelabresib-in-Myelofibrosis-Including-Potenti-42523424/ Persons John Mascarenhas Title MorphoSys: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 (EQS Newswire) Media name/outlet Avanza Bank AB Country/Territory Sweden Date 11/12/22 URL https://www.avanza.se/placera/pressmeddelanden/2022/12/11/morphosys-morphosys-presents-new-longer-term-phase-2-results-on-pelabresib-in-myelofibrosis-including-potential-disease-modifying-activity-at-ash-2022.html Persons John Mascarenhas Title EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 (english) Media name/outlet dpa-AFX International ProFeed Country/Territory Germany Date 11/12/22 Persons John Mascarenhas Title EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Media name/outlet AWP OTS (Original text service) - English Country/Territory Switzerland Date 11/12/22 Persons John Mascarenhas Title EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022 Media name/outlet EQS Newsfeed (English) Country/Territory Germany Date 11/12/22 Persons John Mascarenhas